Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM. The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in […]
Featured
Insulet reports 21% sales growth in Q1, raises 2023 guidance
Insulet [WtwhTicker symbol=”PODD”](Nasdaq:PODD)[/WtwhTicker] shares are up on first-quarter results that topped the consensus forecast. Shares of PODD rose more than 3% to 331.60 apiece by midday trading today. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly. The Acton, Massachusetts–based automated insulin delivery technology developer […]
Tandem stock dips after hours on Q1 misses as it teases 2023 product launches
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked down after hours today on first-quarter results that fell shy of the consensus forecast. Shares of TNDM fell 9.9% to $36 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.3%. The […]
Sernova, AstraZeneca collaborate to deliver therapeutic cells with Sernova Cell Pouch
Sernova announced today that it entered into a preclinical research collaboration on drug delivery with AstraZeneca. The collaboration aims to evaluate the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural […]
UK study backs Dexcom real-time CGM
Dexcom (Nasdaq:DXCM) announced today that a published study in the UK supports its real-time continuous glucose monitoring (rtCGM). San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.” The […]
Dexcom proposes $1B offering of convertible senior notes
Dexcom (Nasdaq:DXCM) today announced that it intends to offer $1 billion in convertible senior notes due in 2028. The continuous glucose monitor (CGM) maker made its private placement to persons reasonably considered qualified institutional buyers. San Diego-based Dexcom also plans to grant the initial purchasers of the notes an option to buy more. Those options […]
Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK
Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery. Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 […]
Dexcom grows revenues 18% in Street-beating Q1, raises guidance
Dexcom (Nasdaq:DXCM) today announced that it’s raising its 2023 financial guidance following strong first-quarter financial results. Shares of DXCM dipped 3.7% to $119 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. The San Diego-based continuous glucose monitor […]
Dexcom G6 picks up coverage expansion in Canada
Dexcom (Nasdaq:DXCM) today said it applauds an expansion of coverage for continuous glucose monitoring (CGM) systems in Canada. The coverage expansion comes through the Non-Insured Health Benefits (NIHB) program. It now enables any client managing diabetes with insulin to access the standard of care. Dexcom said its G6 CGM is now at its most accessible point […]
Humacyte, JDRF to develop biovascular pancreas to treat type 1 diabetes
Humacyte (Nasdaq:HUMA) and JDRF announced today that they entered into a collaboration to develop a biovascular pancreas (BVP). The collaboration aims to advance the development of Humacyte’s BVP product candidate for treating type 1 diabetes. Humacyte designed its BVP to deliver insulin-producing islets using its investigational, tissue-engineered blood vessel. The company calls it the Human […]
